scholarly journals Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: From Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure

10.5772/28150 ◽  
2011 ◽  
Author(s):  
Pedro A. ◽  
Jorge Berlanga-Acosta ◽  
Jose I. ◽  
Carmen Valenzuela-Silva ◽  
Odalys Gonzalez-Diaz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Proof Of Concept ◽  
Efficacy And Safety ◽  
Epidermal Growth

Cloning of Novel Epidermal Growth Factor (EGF) Plasmid for Gene Therapy on Diabetic Foot Ulcer

2008 ◽  
Vol 32 (2) ◽  
pp. 131 ◽  
Author(s):  
Hye Sook Chung ◽  
Chang Shin Yoon ◽  
Min Jeong Kwon ◽  
Mi Kyung Kim ◽  
Soon Hee Lee ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Epidermal Growth

scholarly journals Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure

2009 ◽  
Vol 6 (1) ◽  
pp. 67-72 ◽  
Author(s):  
José I Fernández-Montequín ◽  
Blas Y Betancourt ◽  
Gisselle Leyva-Gonzalez ◽  
Ernesto L Mola ◽  
Katia Galán-Naranjo ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Wound Closure ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Intralesional Administration ◽  
Epidermal Growth ◽  
Ulcer Treatment

scholarly journals Intralesional epidermal growth factor application is a potential therapeutic strategy to improve diabetic foot ulcer healing and prevent amputation

2020 ◽  
Vol 36 (1) ◽  
pp. 15-22
Author(s):  
Ömer Arda Çetinkaya ◽  
Süleyman Utku Çelik ◽  
Miraç Barış Erzincan ◽  
Barış Hazır ◽  
Hakan Uncu
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ulcer Healing ◽  
Diabetic Foot ◽  
Therapeutic Strategy ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Epidermal Growth

Can Intralesional Epidermal Growth Factor Reduce Skin Graft Applications in Patients with Diabetic Foot Ulcer?

2021 ◽  
Vol 111 (5) ◽  
Author(s):  
Bayram Colak ◽  
Serdar Yormaz ◽  
Ilhan Ece ◽  
Mustafa Sahin
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Donor Site ◽  
Graft Loss ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Major Amputation ◽  
Duration Of Treatment ◽  
Epidermal Growth

Background Diabetic foot ulcer (DFU) is a serious health problem. Major amputation increases the risk of mortality in patients with DFU; therefore, treatment methods other than major amputation come to the fore for these patients. Graft applications create an appropriate environment for the reproduction of epithelial cells. Similarly, epidermal growth factor (EGF) also stimulates epithelization and increases epidermis formation. In this study, we aimed to compare patients with DFU treated with EGF and those treated with a split-thickness skin graft. Methods Patients who were treated for DFU in the general surgery clinic were included in the study. The patients were evaluated retrospectively according to their demographic characteristics, wound characteristics, duration of treatment, and treatment modalities. Results There were 26 patients in the EGF group and 21 patients in the graft group. The mean duration of treatment was 7 weeks (4-8 weeks) in the EGF group and 5.3 weeks (4-8 weeks) in the graft group (P < .05). In the EGF group, wound healing could not be achieved in one patient during the study period. In the graft group, no recovery was achieved in three patients (14.2%) in the donor site. Graft loss was detected in four patients (19%), and partial graft loss was observed in three patients (14.2%). The DFU of these patients were on the soles (85.7%). These patients have multiple comorbidities. Conclusions EGF application may be preferred to avoid graft complications in the graft area and the donor site, especially in elderly patients with multiple comorbidities and wounds on the soles.

An Assessment of Intralesional Epidermal Growth Factor for Treating Diabetic Foot Wounds

2017 ◽  
Vol 107 (1) ◽  
pp. 17-29 ◽  
Author(s):  
Bulent M. Ertugrul ◽  
Benjamin A. Lipsky ◽  
Ulas Guvenc ◽  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Diabetic Foot ◽  
Foot Ulcer ◽  
Diabetic Foot Ulcer ◽  
Complete Response ◽  
Major Amputation ◽  
Median Frequency ◽  
Surgical Interventions ◽  
Epidermal Growth

Background: Intralesional epidermal growth factor (EGF) has been available as a medication in Turkey since 2012. We present the results of our experience using intralesional EGF in Turkey for patients with diabetic foot wounds. Methods: A total of 174 patients from 25 Turkish medical centers were evaluated for this retrospective study. We recorded the data on enrolled individuals on custom-designed patient follow-up forms. Patients received intralesional injections of 75 μg of EGF three times per week and were monitored daily for adverse reactions to treatment. Patients were followed up for varying periods after termination of EGF treatments. Results: Median treatment duration was 4 weeks, and median frequency of EGF administration was 12 doses. Complete response (granulation tissue >75% or wound closure) was observed in 116 patients (66.7%). Wounds closed with only EGF administration in 81 patients (46.6%) and in conjunction with various surgical interventions after EGF administration in 65 patients (37.3%). Overall, 146 of the wounds (83.9%) were closed at the end of therapy. Five patients (2.9%) required major amputation. Adverse effects were reported in 97 patients (55.7%). Conclusions: In patients with diabetic foot ulcer who received standard care, additional intralesional EGF application after infection control provided high healing rates with low amputation rates.

Sign in / Sign up

Export Citation Format

Share Document